Last reviewed: June 16, 2026
Last updated: June 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 medications like semaglutide have transformed weight management for millions, yet they are not appropriate for everyone. Understanding contraindications—conditions that make a treatment inadvisable or unsafe—is essential before beginning therapy. PlexusDx helps patients identify whether GLP-1 compounds align with their health profile.
Personal or Family History of Medullary Thyroid Cancer
Medullary thyroid carcinoma (MTC) is a rare but serious cancer affecting thyroid C-cells that produce calcitonin. GLP-1 receptor agonists have demonstrated the ability to stimulate calcitonin secretion in animal studies, raising theoretical concerns about MTC growth or recurrence. The FDA requires a black-box warning on all GLP-1 medications due to this risk, even though no human cases have been definitively linked to the drugs.
Patients with personal MTC history or Multiple Endocrine Neoplasia type 2 (MEN2) syndrome—which includes familial MTC—should not use semaglutide, tirzepatide, or any GLP-1 compound. This restriction applies regardless of body weight, metabolic status, or how well other treatments might work. A thorough family medical history interview is a critical first step before starting any GLP-1 therapy.
Pregnancy, Breastfeeding, and Plans to Become Pregnant
GLP-1 medications have not been studied in pregnant people, and animal reproduction studies have raised developmental concerns. Current guidance recommends discontinuing semaglutide and tirzepatide at least two months before attempting conception due to the long half-life of these compounds in the body. Weight loss itself during pregnancy can reduce nutrient availability to the fetus, making GLP-1 therapy an unnecessary added risk.
Breastfeeding individuals should also avoid GLP-1 medications, as it remains unknown whether these peptides transfer into breast milk or how they might affect nursing infants. Women of childbearing age using PlexusDx semaglutide or other GLP-1 compounds must maintain reliable contraception and inform their prescribing provider immediately if pregnancy occurs. Post-pregnancy, a medical team can reassess safety before resuming treatment.
Type 1 Diabetes and Severe Kidney Disease
GLP-1 agonists were originally developed for type 2 diabetes, not type 1. Type 1 is an autoimmune condition requiring insulin replacement, and GLP-1 medications do not address the underlying pancreatic beta-cell destruction. Adding a GLP-1 drug to type 1 diabetes management can create dangerous drug interactions and unpredictable blood sugar fluctuations without providing the intended benefit.
Severe kidney disease (end-stage renal disease or eGFR below 15 mL/min/1.73m²) represents another critical contraindication. GLP-1 medications are renally cleared, meaning impaired kidney function prevents safe elimination from the body, leading to toxic accumulation. Patients on dialysis or with advanced chronic kidney disease should consult nephrologists before considering any GLP-1 compound, including affordable options like PlexusDx semaglutide injections.
History of Pancreatitis, Gastroparesis, and Gastrointestinal Surgery
Acute or chronic pancreatitis—inflammation of the pancreas—is a relative contraindication to GLP-1 use. Although the mechanism is not fully understood, case reports suggest GLP-1 agonists may trigger or worsen pancreatitis in susceptible individuals. Patients with any history of unexplained severe abdominal pain, recurrent pancreatitis, or alcohol-related pancreatic disease should discuss alternatives with their doctor before starting therapy.
Gastroparesis, a condition in which the stomach empties food too slowly, worsens significantly with GLP-1 medications because these drugs slow gastric motility as part of their mechanism. Similarly, patients with a history of gastric bypass, gastric banding, or other weight-loss surgery may experience compounded nausea, vomiting, or obstruction when combining GLP-1 therapy with prior anatomical changes. A thorough surgical history is essential during the PlexusDx intake process.
Severe Hypersensitivity and Medication Allergies
A documented severe allergy or hypersensitivity reaction to semaglutide, tirzepatide, or other GLP-1 agonists is an absolute contraindication. Reactions can include anaphylaxis, Stevens-Johnson syndrome, or severe angioedema. Patients with known peptide allergies or those who experienced adverse reactions to prior GLP-1 trials should not attempt therapy again without specialist evaluation.
PlexusDx provides compounded versions from licensed 503A pharmacies, which may use slightly different excipients than brand-name formulations. However, the active peptide remains identical, so a true GLP-1 allergy will persist regardless of the source. Patients with questionable past reactions should obtain detailed medical records to clarify whether the response was a true allergy versus expected side effects like nausea or injection-site irritation.
Uncontrolled or Severe Mental Health Conditions
GLP-1 medications can affect appetite, energy levels, and mood, creating complexity for individuals with active depression, bipolar disorder, or eating disorders. Rapid appetite suppression may exacerbate restrictive eating patterns in those with anorexia nervosa or bulimia, turning a therapeutic tool into a harmful enabler. Psychiatric assessment before starting GLP-1 therapy is important, particularly for patients with histories of disordered eating.
While GLP-1 medications are not psychiatric medications, their metabolic effects can influence mental health treatment plans. Severe, uncontrolled depression or psychosis should be stabilized first; GLP-1 therapy can be reconsidered once psychiatric symptoms are managed. Patients considering PlexusDx semaglutide or other GLP-1 compounds should have open conversations with both their mental health provider and prescribing clinician about timing and safety.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can someone with type 2 diabetes take GLP-1 medications if they also have a thyroid condition?
Type 2 diabetes is compatible with GLP-1 therapy in most cases, and many thyroid conditions are safe as well. However, a personal or family history of medullary thyroid cancer is an absolute contraindication. PlexusDx providers review full thyroid and cancer history during intake to ensure safety before prescribing semaglutide or other compounds.
What clinical evidence supports avoiding GLP-1 use in pregnancy?
Animal reproduction studies have shown fetal abnormalities at high GLP-1 doses, though human pregnancy data remains limited. Additionally, intentional weight loss during pregnancy can reduce caloric and nutrient transfer to the fetus. The FDA recommends stopping GLP-1 medications two months before conception to allow clearance from the body.
How much does semaglutide cost at PlexusDx, and is it covered if I have contraindications?
PlexusDx semaglutide injection starts at $149/month with no insurance required, and PlexusDx serves all 50 states. However, if you have a contraindication like medullary thyroid cancer history or pregnancy, semaglutide is medically inappropriate regardless of cost. A clinical assessment is the first step before any pricing discussion.
Are there GLP-1 alternatives if someone cannot safely take standard compounds?
Patients with contraindications to GLP-1 agonists may explore older weight-loss medications like phentermine or orlistat, or consider non-pharmacologic approaches like intensive lifestyle modification and bariatric surgery consultation. PlexusDx providers can discuss alternatives during a comprehensive health assessment, though their specialty is GLP-1-based therapy.
Does the PlexusDx Precision Peptide Genetic Test reveal genetic contraindications to GLP-1 use?
The Precision Peptide Genetic Test identifies genetic variations affecting GLP-1 and GIP receptor sensitivity, appetite pathways, and metabolic traits—not contraindications. This $99 add-on test analyzes 14 pathways and 150+ genetic insights to predict individual response, but it does not replace medical screening for serious conditions like MTC history or pregnancy, which remain absolute barriers to treatment.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Take GLP-1 While Nursing? Understanding the Safety of Semaglutide and Tirzepatide for Breastfeeding Mothers
Who Should Not Use GLP-1: Understanding the Risks and Considerations